(1) American Family Physician, The American Academy of Family Physicians, An Algorithm for the
Evaluation of Peripheral Neuropathy
, Feb 15, 1998 , CLICK HERE to read the article.    

(2) Berkson BM.
A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of
alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories
. Med Klin. 1999;94 Suppl 3:84-
89,
CLICK HERE to read the article

(3) Konlee M. New treatments for hepatitis B and C [antigen-specific transfer for A, B & C (chisolm
biologicals) and thymate]
. Posit Health News. 1998 Fall;(No 17):19-21

(4) van der Goes A, Brouwer J, Hoekstra K, Roos D, van den Berg TK, Dijkstra CD.
Reactive oxygen species
are required for the
phagocytosis of myelin by macrophages. J Neuroimmunol. 1998 Dec 1;92(1-2):67-75,
CLICK HERE to read the article.

(5) Morini M, Roccatagliata L, Dell'Eva R, Pedemonte E, Furlan R, Minghelli S, Giunti D, Pfeffer U, Marchese
M, Noonan D, Mancardi G, Albini A, Uccelli A. of the Molecular Oncology Laboratory, National Cancer
Research Institute, Genoa, Italy.
Alpha-lipoic acid is effective in prevention and treatment of experimental
autoimmune encephalomyelitis
. J Neuroimmunol. 2004 Mar;148(1-2):146-53. CLICK HERE to read the article.

(6) Marracci GH, Jones RE, McKeon GP, Bourdette DN of the Department of Neurology, Oregon Health and
Science University, Portland, OR 97201, USA.
Alpha lipoic acid inhibits T cell migration into the spinal cord
and suppresses and treats experimental autoimmune encephalomyelitis
. J Neuroimmunol. 2002 Oct;131(1-
2):104-14.
CLICK HERE to read the article.

(7) Joseph Mercola, MD. Non-Drug Approaches to Hepatitis C Ignored by "Awareness" Campaign, The
Washington Post, October 31, 2000.
CLICK HERE to read this article.

(8) National Institute of Health, Study Phase, ClinicalTrials.gov

(9) S. C.J. Huijbregts, PhD, N. F. Kalkers, MD PhD, L. M.J. de Sonneville, PhD, V. de Groot, MD PhD, I. E.W.
Reuling, MSc and C. H. Polman, MD PhD.
Differences in cognitive impairment of relapsing remitting,
secondary, and primary progressive MS
, NEUROLOGY 2004;63:335-339, © 2004 American Academy of
Neurology.
CLICK HERE to read this abstract

(10) MedMaster™, a product of the American Society of Health-System Pharmacists (ASHP)

(11) USP DI® Advice for the Patient®, a product of the
United States Pharmacopeia (USP).

(12) Bruce Ames, Senior Scientist at Children's Hospital Oakland Research Institute, California,
Health for
Life
, Newsweek January 17, 2005, pp 52, 55.

(13) Volker Brinkmann, Michael D. Davis, Christopher E. Heise, Rainer Albert, Sylvain Cottens, Robert Hof,
Christian Bruns, Eva Prieschl, Thomas Baumruker, Peter Hiestand, Carolyn A. Foster, Markus Zollinger, and
Kevin R. Lynch.
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors9, The Journal
of  Biological Chemistry, Vol. 277, No. 24, Issue of June 14, pp. 21453–21457, 2002.
CLICK HERE to read
this article.






Information that is provided in this site is not intended as a substitute for the medical advice of physicians.